160 related articles for article (PubMed ID: 37749238)
21. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
[TBL] [Abstract][Full Text] [Related]
22. One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals.
Guo Q; Zhao C; Gao X; Ding L; Wang P; Ren Y; Hou X; Yao Y; Zhang C; Yang X; Yang Z; Zhu H
Mol Pharm; 2023 Jul; 20(7):3672-3682. PubMed ID: 37212215
[TBL] [Abstract][Full Text] [Related]
23. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.
Newman JR; Gleysteen JP; Barañano CF; Bremser JR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2008 Jul; 7(7):1063-70. PubMed ID: 18431087
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
Śmiłowicz D; Schlyer D; Boros E; Meimetis L
Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
[TBL] [Abstract][Full Text] [Related]
27. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-D-glucose in human pancreatic carcinoma xenografts and in inflammation models.
Hellwig D; Menges M; Schneider G; Moellers MO; Romeike BF; Menger MD; Kirsch CM; Samnick S
Nucl Med Biol; 2005 Feb; 32(2):137-45. PubMed ID: 15721759
[TBL] [Abstract][Full Text] [Related]
28. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
29. Intra-individual dynamic comparison of
Piron S; Verhoeven J; Descamps B; Kersemans K; De Man K; Van Laeken N; Pieters L; Vral A; Vanhove C; De Vos F
Sci Rep; 2020 Dec; 10(1):21068. PubMed ID: 33273603
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
31. PET Imaging of
Liu F; Xu X; Zhu H; Zhang Y; Yang J; Zhang L; Li N; Zhu L; Kung HF; Yang Z
Mol Pharm; 2018 Aug; 15(8):3448-3455. PubMed ID: 29985631
[TBL] [Abstract][Full Text] [Related]
32. Development of [
Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
[TBL] [Abstract][Full Text] [Related]
33. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
[TBL] [Abstract][Full Text] [Related]
34. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
35. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
36. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
37. Exploration of radionuclide labeling of a novel scFv-Fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment.
Li D; Ding L; Chen Y; Wang Z; Zeng Z; Ma X; Huang H; Li H; Qian X; Yang Z; Zhu H
Eur J Med Chem; 2024 Feb; 266():116134. PubMed ID: 38266552
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Bioevaluation of Novel [
Yang X; Wang F; Zhu H; Yang Z; Chu T
Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
[TBL] [Abstract][Full Text] [Related]
39. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
[TBL] [Abstract][Full Text] [Related]
40. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
